Alynni (Alectinib)

$1 / Price
  • Brand Name:
  • Origin:
  • Small Orders:
    50 Bottles
  • Tags:
Inquire Now Link

  • Details
  • Description
  • Packaging Size
  • Strength
  • Compositon
  • Treatment
    EGFR Lung cancer
  • Form
  • Brand
  • Quantity Unit
    150mg/C, 56C/Bottle
  • Manufacturer
    Tongmeng (Lao) Pharmaceutical & Food Co., Ltd.

Alectinib marketed as Alynni,Alecensa is an oral drug that blocks the activity of anaplastic lymphoma kinase (ALK) and is used to treat non-small-cell lung cancer (NSCLC). It was developed by Chugai Pharmaceutical Co. Japan.

Medical uses
Alectinib was approved in Japan in July 2014 for the treatment of ALK fusion-gene positive, unresectable, advanced or recurrent non-small-cell lung cancer (NSCLC).

It was granted an accelerated approval by the US Food and Drug Administration (FDA) in December 2015 to treat patients with advanced ALK-positive NSCLC whose disease worsened after, or who could not tolerate, treatment with crizotinib (Xalkori). (This was converted into a full approval in Nov 2017).
It got a conditional approval by the European Medicines Agency in February 2017 for the same indication. This means that additional studies are awaited to confirm a positive benefit-risk-ratio.

The approvals were based mainly on two trials: In a Japanese Phase I–II trial, after approximately 2 years, 19.6% of patients had achieved a complete response, and the 2-year progression-free survival rate was 76%. In February 2016 the J-ALEX phase III study comparing alectinib with crizotinib was terminated early because an interim analysis showed that progression-free survival was longer with alectinib.

In November 2017 the FDA approved alectinib for the first-line treatment of patients with ALK-positive metastatic non-small cell lung cancer. This based on the phase 3 ALEX trial comparing it with crizotinib.

Why is this medication prescribed?
Alectinib is used to treat a certain type of non-small-cell lung cancer (NSCLC) that has spread to other parts of the body. Alectinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.

How should this medicine be used?
Alectinib comes as a capsule to take by mouth. It is usually taken with food twice daily. Take alectinib at around the same times every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take alectinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the capsules whole; do not open or dissolve them.

If you vomit after you take alectinib, do not immediately take another dose. Continue your regular dosing schedule.

Your doctor may temporarily or permanently stop your treatment or decrease your dose if you experience certain side effects of alectinib. Tell your doctor how you are feeling during your treatment. Continue to take alectinib even if you feel well. Do not stop taking alectinib without talking to your doctor.

Ask your pharmacist or doctor for a copy of the manufacturer's information for the patient.

Other uses for this medicine
This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

What side effects can this medication cause?
Alectinib may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:
swelling in your hands, face, or eyelids
weight gain